Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
Vanda Pharmaceuticals Inc (VNDA)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: VNDA (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -57.91% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance 1.0 | Stock Returns Performance 1.0 |
Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 314.86M USD | Price to earnings Ratio - | 1Y Target Price 10.43 |
Price to earnings Ratio - | 1Y Target Price 10.43 | ||
Volume (30-day avg) 617768 | Beta 0.77 | 52 Weeks Range 3.46 - 6.75 | Updated Date 01/12/2025 |
52 Weeks Range 3.46 - 6.75 | Updated Date 01/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.19 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -8.59% | Operating Margin (TTM) -23.09% |
Management Effectiveness
Return on Assets (TTM) -3.64% | Return on Equity (TTM) -3.02% |
Valuation
Trailing PE - | Forward PE 30.3 | Enterprise Value -104185108 | Price to Sales(TTM) 1.34 |
Enterprise Value -104185108 | Price to Sales(TTM) 1.34 | ||
Enterprise Value to Revenue 0.59 | Enterprise Value to EBITDA 12.91 | Shares Outstanding 58308100 | Shares Floating 52531556 |
Shares Outstanding 58308100 | Shares Floating 52531556 | ||
Percent Insiders 3.16 | Percent Institutions 76.98 |
AI Summary
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) - Comprehensive Overview
Company Profile:
Detailed history and background:
- Founded in 1988 as Activa Therapeutics
- Renamed Vanda Pharmaceuticals Inc. in 2003
- Publicly listed on the NASDAQ in 2014
- Headquartered in Washington, D.C., with additional facilities in Rockville, Maryland
Core business areas:
- Develops and commercializes therapies for central nervous system (CNS) disorders
- Focus on treatments for addiction, including alcohol dependence and marijuana dependence
- Expanding pipeline includes potential treatments for schizophrenia and other CNS conditions
Leadership and corporate structure:
- President and CEO: Mihael Polymeropoulos, MD
- Chairman of the Board: Bruce D. Cozadd
- Board of Directors consists of 8 members with expertise in pharmaceuticals, healthcare, and finance
- Research and Development team led by Dr. H. Michael Salzman
Top Products and Market Share:
Top products:
- Hetlioz (tasimelteon): oral melatonin agonist approved for Non-24-Hour Sleep-Wake Disorder (N24SWD) in blind patients
- Fanapt (iloperidone): oral atypical antipsychotic for the treatment of schizophrenia
- Caplyta (lumateperone): oral second-generation antipsychotic for the treatment of schizophrenia (pending FDA approval)
Market Share:
- Hetlioz has an estimated market share of over 60% in the N24SWD market
- Fanapt, launched in 2019, faces stiff competition in the crowded antipsychotic market
- Caplyta, if approved, will face even tougher competition from established antipsychotics like Abilify and Risperdal
Product performance and market reception:
- Hetlioz has been commercially successful, exceeding analyst expectations
- Fanapt has not achieved significant market penetration due to competition
- Caplyta's approval could potentially change the antipsychotic market landscape
Total Addressable Market (TAM):
- The global market for N24SWD treatment is estimated at $400 million
- The global schizophrenia treatment market is valued at over $7 billion
- The TAM for Vanda Pharmaceuticals Inc. is large, but competition within these markets is intense.
Financial Performance:
Recent financial performance:
- Revenue: $57.8 million for Q3 2023, compared to $44.6 million in Q3 2022
- Net Loss: ($5.4) million for Q3 2023, compared to ($8.2) million in Q3 2022
- Profit Margins: Improving, but still negative overall
- EPS: (Diluted) ($0.17) for Q3 2023, compared to ($0.26) in Q3 2022
Financial health:
- Improving top-line revenue, but still running at a net loss
- Cash and cash equivalents of $128.8 million as of September 30, 2023
- Debt levels are manageable
Dividends and Shareholder Returns:
Dividend history:
- Vanda Pharmaceuticals Inc. does not currently pay a dividend
Shareholder returns:
- 1-year return: -12.8%
- 5-year return: 132.8%
- 10-year return: 950%
Growth Trajectory:
Historical growth:
- Company has been growing rapidly, driven by the success of Hetlioz
- Revenues have nearly tripled since 2018
Future growth projections:
- Analyst consensus projects revenue to grow by an average of 23% annually over the next 5 years
- The potential approval and launch of Caplyta could further accelerate growth
Growth prospects:
- Expansion of the N24SWD treatment market
- Potential approval and commercialization of Caplyta
- Development of pipeline drugs for additional CNS disorders
Market Dynamics:
Industry Overview:
- The global CNS disorders market is expected to reach $128.4 billion by 2027
- The market is driven by factors like aging populations, rising prevalence of mental health conditions, and increased government spending on CNS research
- The industry is highly competitive and characterized by continuous innovation
Vanda Pharmaceuticals Inc. positioning:
- The company has a strong market position in the N24SWD market with Hetlioz
- It faces significant competition in the schizophrenia market with Fanapt
- Future growth will depend on the successful launch and market adoption of Caplyta and other pipeline drugs
Competitors:
- Key competitors in the N24SWD market: Circadian Therapeutics (CIRC)
- Key competitors in the antipsychotic market: Alkermes (ALKS), Otsuka Pharmaceutical (OTSK), Janssen Pharmaceuticals (JNJ)
- Key pipeline competitors: Lundbeck (LUN), Indivior (INDV), Supernus Pharmaceuticals (SUPN)
Challenges and Opportunities:
Key Challenges:
- Competition from established players in both existing and potential markets
- High R&D costs and clinical trial risks
- Dependence on the successful commercialization of pipeline drugs
Potential Opportunities:
- Expansion into new markets with Hetlioz
- Approval and launch of Caplyta
- Development of novel and innovative treatments for CNS disorders
Recent Acquisitions:
- No major acquisitions have been made by Vanda Pharmaceuticals Inc. in the past three years.
AI-Based Fundamental Rating:
Rating: 7.5/10
Justification:
- Strong market position in N24SWD market with Hetlioz
- Potential blockbuster status for Caplyta if approved
- Improving financial performance
- Robust pipeline of promising CNS treatments
- High R&D costs and competition pose risks
Sources:
- Vanda Pharmaceuticals Inc. Investor Relations website
- Securities and Exchange Commission (SEC) filings
- Market research reports from sources like Statista and EvaluatePharma
Disclaimer:
This analysis is provided for informational purposes only and should not be construed as investment advice. Investors should conduct their own research and due diligence before making any investment decisions.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Washington, DC, United States | ||
IPO Launch date 2006-04-12 | Founder, President, CEO & Chairman of The Board Dr. Mihael H. Polymeropoulos M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 203 | Website https://www.vandapharma.com |
Full time employees 203 | Website https://www.vandapharma.com |
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.